A lower X-gate in TASK channels traps inhibitors within the vestibule.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
06 2020
Historique:
received: 08 07 2019
accepted: 12 03 2020
pubmed: 6 6 2020
medline: 22 9 2020
entrez: 6 6 2020
Statut: ppublish

Résumé

TWIK-related acid-sensitive potassium (TASK) channels-members of the two pore domain potassium (K

Identifiants

pubmed: 32499642
doi: 10.1038/s41586-020-2250-8
pii: 10.1038/s41586-020-2250-8
doi:

Substances chimiques

Anesthetics 0
Nerve Tissue Proteins 0
Potassium Channels, Tandem Pore Domain 0
potassium channel subfamily K member 3 1HQ3YCN4GS

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

443-447

Subventions

Organisme : Wellcome Trust
ID : 106169/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 109114/Z/15/Z
Pays : United Kingdom

Références

Karschin, C. et al. Expression pattern in brain of TASK-1, TASK-3, and a tandem pore domain K
pubmed: 11749039 doi: 10.1006/mcne.2001.1045
Jones, S. A., Morton, M. J., Hunter, M. & Boyett, M. R. Expression of TASK-1, a pH-sensitive twin-pore domain K
pubmed: 12063289 doi: 10.1152/ajpheart.00963.2001
Putzke, C. et al. The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc. Res. 75, 59–68 (2007).
pubmed: 17389142 doi: 10.1016/j.cardiores.2007.02.025
Decher, N. et al. Knock-out of the potassium channel TASK-1 leads to a prolonged QT interval and a disturbed QRS complex. Cell. Physiol. Biochem. 28, 77–86 (2011).
pubmed: 21865850 doi: 10.1159/000331715
Olschewski, A. et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ. Res. 98, 1072–1080 (2006).
pubmed: 16574908 doi: 10.1161/01.RES.0000219677.12988.e9
Donner, B. C. et al. Functional role of TASK-1 in the heart: studies in TASK-1-deficient mice show prolonged cardiac repolarization and reduced heart rate variability. Basic Res. Cardiol. 106, 75–87 (2011).
pubmed: 20978771 doi: 10.1007/s00395-010-0128-x
Gurney, A. M. et al. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. Circ. Res. 93, 957–964 (2003).
pubmed: 14551239 doi: 10.1161/01.RES.0000099883.68414.61
Steinberg, E. A., Wafford, K. A., Brickley, S. G., Franks, N. P. & Wisden, W. The role of K
pubmed: 25482669 doi: 10.1007/s00424-014-1654-4
Putzke, C. et al. Differential effects of volatile and intravenous anesthetics on the activity of human TASK-1. Am. J. Physiol. Cell Physiol. 293, C1319–C1326 (2007).
pubmed: 17699638 doi: 10.1152/ajpcell.00100.2007
Patel, A. J. et al. Inhalational anesthetics activate two-pore-domain background K
pubmed: 10321245 doi: 10.1038/8084
Sirois, J. E., Lei, Q., Talley, E. M., Lynch, C., III & Bayliss, D. A. The TASK-1 two-pore domain K
pubmed: 10964940 pmcid: 6772985 doi: 10.1523/JNEUROSCI.20-17-06347.2000
Duprat, F. et al. TASK, a human background K
pubmed: 9312005 pmcid: 1170177 doi: 10.1093/emboj/16.17.5464
Talley, E. M. & Bayliss, D. A. Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels: volatile anesthetics and neurotransmitters share a molecular site of action. J. Biol. Chem. 277, 17733–17742 (2002).
pubmed: 11886861 doi: 10.1074/jbc.M200502200
Lopes, C. M. et al. PIP2 hydrolysis underlies agonist-induced inhibition and regulates voltage gating of two-pore domain K
pubmed: 15677683 pmcid: 1456043 doi: 10.1113/jphysiol.2004.081935
Wilke, B. U. et al. Diacylglycerol mediates regulation of TASK potassium channels by Gq-coupled receptors. Nat. Commun. 5, 5540 (2014).
pubmed: 25420509 doi: 10.1038/ncomms6540
Kiper, A. K. et al. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea? Pflugers Arch. 467, 1081–1090 (2015).
pubmed: 25511502 doi: 10.1007/s00424-014-1665-1
Miller, A. N. & Long, S. B. Crystal structure of the human two-pore domain potassium channel K
pubmed: 22282804 doi: 10.1126/science.1213274
Brohawn, S. G., del Mármol, J. & MacKinnon, R. Crystal structure of the human K
pubmed: 22282805 pmcid: 3329120 doi: 10.1126/science.1213808
Brohawn, S. G., Campbell, E. B. & MacKinnon, R. Domain-swapped chain connectivity and gated membrane access in a Fab-mediated crystal of the human TRAAK K
pubmed: 23341632 doi: 10.1073/pnas.1218950110
Dong, Y. Y. et al. K
pubmed: 25766236 pmcid: 6034649 doi: 10.1126/science.1261512
Lolicato, M. et al. K
pubmed: 28693035 pmcid: 5778891 doi: 10.1038/nature22988
Morton, M. J., O’Connell, A. D., Sivaprasadarao, A. & Hunter, M. Determinants of pH sensing in the two-pore domain K
pubmed: 12634929 doi: 10.1007/s00424-002-0901-2
Stansfeld, P. J. et al. Insight into the mechanism of inactivation and pH sensitivity in potassium channels from molecular dynamics simulations. Biochemistry 47, 7414–7422 (2008).
pubmed: 18558719 doi: 10.1021/bi800475j
Goldstein, M. et al. Functional mutagenesis screens reveal the ‘cap structure’ formation in disulfide-bridge free TASK channels. Sci. Rep. 6, 19492 (2016).
pubmed: 26794006 pmcid: 4726246 doi: 10.1038/srep19492
Klesse, G., Rao, S., Sansom, M. S. P. & Tucker, S. J. CHAP: a versatile tool for the structural and functional annotation of ion channel pores. J. Mol. Biol. 431, 3353–3365 (2019).
pubmed: 31220459 pmcid: 6699600 doi: 10.1016/j.jmb.2019.06.003
Streit, A. K. et al. A specific two-pore domain potassium channel blocker defines the structure of the TASK-1 open pore. J. Biol. Chem. 286, 13977–13984 (2011).
pubmed: 21362619 pmcid: 3077598 doi: 10.1074/jbc.M111.227884
Piechotta, P. L. et al. The pore structure and gating mechanism of K
pubmed: 21822218 pmcid: 3181484 doi: 10.1038/emboj.2011.268
Rinné, S. et al. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes. J. Mol. Cell. Cardiol. 81, 71–80 (2015).
pubmed: 25655935 doi: 10.1016/j.yjmcc.2015.01.017
Renigunta, V. et al. Much more than a leak: structure and function of K
pubmed: 25791628 doi: 10.1007/s00424-015-1703-7
Sterbulac, D. Molecular determinants of chemical modulation of two-pore domain potassium channels. Chem. Biol. Drug Design 94, 1596–1614 (2019).
doi: 10.1111/cbdd.13571
Delbeck, M. et al. 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of TASK-1 and TASK-3 channels, for the treatment of sleep-related breathing disorders. WIPO patent WO2017097792A1 (2017).
Chokshi, R. H., Larsen, A. T., Bhayana, B. & Cotten, J. F. Breathing stimulant compounds inhibit TASK-3 potassium channel function likely by binding at a common site in the channel pore. Mol. Pharmacol. 88, 926–934 (2015).
pubmed: 26268529 pmcid: 4613942 doi: 10.1124/mol.115.100107
Ma, L. et al. A novel channelopathy in pulmonary arterial hypertension. N. Engl. J. Med. 369, 351–361 (2013).
pubmed: 23883380 pmcid: 3792227 doi: 10.1056/NEJMoa1211097
Barel, O. et al. Maternally inherited Birk Barel mental retardation dysmorphism syndrome caused by a mutation in the genomically imprinted potassium channel KCNK9. Am. J. Hum. Genet. 83, 193–199 (2008).
pubmed: 18678320 pmcid: 2495061 doi: 10.1016/j.ajhg.2008.07.010
Sediva, M. et al. Novel variant in the KCNK9 gene in a girl with Birk Barel syndrome. Eur. J. Med. Genet. 63, 103619 (2020).
Armstrong, C. M. Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J. Gen. Physiol. 58, 413–437 (1971).
pubmed: 5112659 pmcid: 2226036 doi: 10.1085/jgp.58.4.413
Bolshakov, K. V., Gmiro, V. E., Tikhonov, D. B. & Magazanik, L. G. Determinants of trapping block of N-methyl-d-aspartate receptor channels. J. Neurochem. 87, 56–65 (2003).
pubmed: 12969252 doi: 10.1046/j.1471-4159.2003.01956.x
Linder, T., Saxena, P., Timin, E., Hering, S. & Stary-Weinzinger, A. Structural insights into trapping and dissociation of small molecules in K
pubmed: 25297379 doi: 10.1021/ci500353r
Sitsel, O., Wang, K., Liu, X. & Gourdon, P. Crystallization of P-type ATPases by the high lipid-detergent (HiLiDe) method. Methods Mol. Biol. 1377, 413–420 (2016).
pubmed: 26695052 doi: 10.1007/978-1-4939-3179-8_37
Kabsch, W. Xds. Acta Crystallogr. D 66, 125–132 (2010).
pubmed: 20124692 doi: 10.1107/S0907444909047337
Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D 62, 72–82 (2006).
pubmed: 16369096 doi: 10.1107/S0907444905036693
Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235–242 (2011).
pubmed: 21460441 doi: 10.1107/S0907444910045749
STARANISO (Global Phasing, 2018).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840 pmcid: 2483472 doi: 10.1107/S0021889807021206
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
pubmed: 20124702 doi: 10.1107/S0907444909052925
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
pubmed: 20383002 doi: 10.1107/S0907444910007493
BUSTER v.2.10.0 (Global Phasing, 2011).
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861–877 (2019).
doi: 10.1107/S2059798319011471
Zuzarte, M. et al. Intracellular traffic of the K
pubmed: 19139046 pmcid: 2673767 doi: 10.1113/jphysiol.2008.164756
Rinné, S. et al. The molecular basis for an allosteric inhibition of K
pubmed: 30803485 pmcid: 6391080 doi: 10.7554/eLife.39476
The PyMOL Molecular Graphics System v.1.7.7.1 (Schrödinger, 2010).
Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson–Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665–W667 (2004).
pubmed: 441519 pmcid: 441519 doi: 10.1093/nar/gkh381
Jurrus, E. et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci. 27, 112–128 (2018).
pubmed: 28836357 doi: 10.1002/pro.3280
Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
pubmed: 21988835 pmcid: 3261699 doi: 10.1038/msb.2011.75
Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M. & Barton, G. J. Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189–1191 (2009).
pubmed: 19151095 pmcid: 2672624 doi: 10.1093/bioinformatics/btp033
Bond, C. S. & Schüttelkopf, A. W. ALINE: a WYSIWYG protein-sequence alignment editor for publication-quality alignments. Acta Crystallogr. D 65, 510–512 (2009).
pubmed: 19390156 doi: 10.1107/S0907444909007835

Auteurs

Karin E J Rödström (KEJ)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Aytuğ K Kiper (AK)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior - MCMBB, University of Marburg, Marburg, Germany.

Wei Zhang (W)

Structural Genomics Consortium, University of Oxford, Oxford, UK.
Public Technology Service Center and CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

Susanne Rinné (S)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior - MCMBB, University of Marburg, Marburg, Germany.

Ashley C W Pike (ACW)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Matthias Goldstein (M)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior - MCMBB, University of Marburg, Marburg, Germany.

Linus J Conrad (LJ)

Department of Physics, University of Oxford, Oxford, UK.
Department of Biomedical Science, University of Sheffield, Sheffield, UK.

Martina Delbeck (M)

Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.

Michael G Hahn (MG)

Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.

Heinrich Meier (H)

Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.

Magdalena Platzk (M)

Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.

Andrew Quigley (A)

Structural Genomics Consortium, University of Oxford, Oxford, UK.
Membrane Protein Laboratory, Research Complex at Harwell, Harwell, UK.

David Speedman (D)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Leela Shrestha (L)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Shubhashish M M Mukhopadhyay (SMM)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Nicola A Burgess-Brown (NA)

Structural Genomics Consortium, University of Oxford, Oxford, UK.

Stephen J Tucker (SJ)

Department of Physics, University of Oxford, Oxford, UK.

Thomas Müller (T)

Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany.

Niels Decher (N)

Institute for Physiology and Pathophysiology, Vegetative Physiology and Marburg Center for Mind, Brain and Behavior - MCMBB, University of Marburg, Marburg, Germany. decher@staff.uni-marburg.de.

Elisabeth P Carpenter (EP)

Structural Genomics Consortium, University of Oxford, Oxford, UK. liz.carpenter@sgc.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH